<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660617</url>
  </required_header>
  <id_info>
    <org_study_id>MOSMPCA</org_study_id>
    <nct_id>NCT04660617</nct_id>
  </id_info>
  <brief_title>A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)</brief_title>
  <official_title>A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to perform multi-omics technologies, including genomic,&#xD;
      transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate&#xD;
      cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct&#xD;
      tumor subtypes and finding new treatment targets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is the commonest malignancy and the second leading cause of tumor-related&#xD;
      death among males worldwide. Though patients with early stage prostate cancer can obtain&#xD;
      satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis&#xD;
      of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant&#xD;
      prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of&#xD;
      the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic&#xD;
      methods. These techniques are promising in uncovering the mechanism of the tumor progression,&#xD;
      identifying distinct tumor subtypes and finding new treatment targets.&#xD;
&#xD;
      In the current prospective study, the investigators plan to perform multi-omics technologies&#xD;
      in patients with mPCa, aiming at uncovering the mechanism of the tumor progression,&#xD;
      identifying distinct tumor subtypes and finding new treatment targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Genetic profiling results</measure>
    <time_frame>From baseline (initial diagnosis of PCa), until study completion (48 months)</time_frame>
    <description>Mutation identified via whole-genome sequencing will be recored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcriptional profiling results</measure>
    <time_frame>From baseline (initial diagnosis of PCa), until study completion (48 months)</time_frame>
    <description>Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epigenomic profiling results</measure>
    <time_frame>From baseline (initial diagnosis of PCa), until study completion (48 months)</time_frame>
    <description>Determining the epigenomic status of specific genes by performing DNA-methylation sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein expression results</measure>
    <time_frame>From baseline (initial diagnosis of PCa), until study completion (48 months)</time_frame>
    <description>Determing the expression status of centain proteins by performing immunohistochemistry in prostate biopsy specimen</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary metastatic prostate cancer are potentially eligible for the current&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological confirmation of prostate cancer&#xD;
&#xD;
          -  Age: â‰¥40 years old&#xD;
&#xD;
          -  Bone or visceral metastatic disease confirmed by image examination.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients harbouring other types of cancer besides prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only male patient can enter this study</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Zeng, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinge Zhao, Dr.</last_name>
    <phone>86 13679017572</phone>
    <email>jingezhao@foxmail.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Hao Zeng</investigator_full_name>
    <investigator_title>Vice director of the department of urology</investigator_title>
  </responsible_party>
  <keyword>Genomic sequencing</keyword>
  <keyword>Transcriptome sequencing</keyword>
  <keyword>Epigenetics</keyword>
  <keyword>Metabonomics</keyword>
  <keyword>Immunohistochemical</keyword>
  <keyword>Multi-omics Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

